These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3784982)

  • 1. Ara-C syndrome during low-dose continuous infusion therapy.
    Powell BL; Zekan PJ; Muss HB; Richards F; Lyerly ES; Capizzi RL
    Med Pediatr Oncol; 1986; 14(6):310-2. PubMed ID: 3784982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of a continuous infusion of high-dose ara-C in conjunction with a fixed dose of 2'-deoxycytidine (IND 28108) in patients with refractory leukemia: an interim report.
    Grant S; Baker M; Bhalla K
    Leukemia; 1993 Dec; 7(12):1933-8. PubMed ID: 8255091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of intermittent continuous infusion high dose cytosine arabinoside for acute leukemia.
    Stone RM; Spriggs DR; Dhawan RK; Arthur KA; Mayer RJ; Kufe DW
    Leukemia; 1990 Dec; 4(12):843-7. PubMed ID: 2243507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cytarabine-induced pericarditis].
    Yamada T; Tsurumi H; Hara T; Sawada M; Oyama M; Moriwaki H
    Rinsho Ketsueki; 1998 Nov; 39(11):1115-20. PubMed ID: 9866424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dose ara-C administered by continuous subcutaneous infusion: a pharmacologic evaluation.
    Spriggs DR; Sokal JE; Griffin J; Kufe DW
    Cancer Drug Deliv; 1986; 3(3):211-6. PubMed ID: 3779605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous infusion high-dose cytosine arabinoside in refractory childhood leukemia.
    Ochs J; Sinkule JA; Danks MK; Look AT; Bowman WP; Rivera G
    J Clin Oncol; 1984 Oct; 2(10):1092-7. PubMed ID: 6593435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cytosine arabinoside (Ara-C) syndrome.
    Castleberry RP; Crist WM; Holbrook T; Malluh A; Gaddy D
    Med Pediatr Oncol; 1981; 9(3):257-64. PubMed ID: 6941069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia.
    Winter JN; Variakojis D; Gaynor ER; Larson RA; Miller KB
    Cancer; 1985 Aug; 56(3):443-9. PubMed ID: 3859362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
    Kreis W; Budman DR; Chan K; Allen SL; Schulman P; Lichtman S; Weiselberg L; Schuster M; Freeman J; Akerman S
    Leukemia; 1991 Nov; 5(11):991-8. PubMed ID: 1961042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The clinical effect of low-dose Ara-C in patients with refractory acute nonlymphocytic leukemia and myelodysplastic syndrome].
    Yoshida M; Tsunoda S; Akutsu M; Furukawa Y; Takeda K; Akashi M; Komatsu N; Muroi K; Ikeda K; Ohsaka A
    Gan To Kagaku Ryoho; 1987 Apr; 14(4):1057-62. PubMed ID: 3566302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update.
    Wolff SN; Herzig RH; Phillips GL; Lazarus HM; Greer JP; Stein RS; Ray WA; Herzig GP
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):12-7. PubMed ID: 3589687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias.
    Periclou AP; Avramis VI
    Cancer Chemother Pharmacol; 1996; 39(1-2):42-50. PubMed ID: 8995498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged high dose ARA-C infusions in acute leukemia.
    Spriggs DR; Robbins G; Arthur K; Mayer RJ; Kufe D
    Leukemia; 1988 May; 2(5):304-6. PubMed ID: 3287017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extremely prolonged continuous intraperitoneal infusion of cytosine arabinoside.
    Kirmani S; Zimm S; Cleary SM; Mowry J; Howell SB
    Cancer Chemother Pharmacol; 1990; 25(6):454-8. PubMed ID: 2311175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug.
    Avramis VI; Weinberg KI; Sato JK; Lenarsky C; Willoughby ML; Coates TD; Ozkaynak MF; Parkman R
    Cancer Res; 1989 Jan; 49(1):241-7. PubMed ID: 2908850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Low-dose cytosine arabinoside (Ara-C) continuous infusion regimen for atypical nonlymphocytic leukemia--clinical study of the remission mechanism by serial chromosomal findings, colony formation and plasma Ara-C concentration].
    Tagawa M; Tomonaga M; Shibata J; Nishino K; Nonaka H; Ikeda S; Suzuyama J; Amenomori T; Matuo T; Kuriyama K
    Rinsho Ketsueki; 1984 Oct; 25(10):1606-17. PubMed ID: 6520937
    [No Abstract]   [Full Text] [Related]  

  • 17. Subacute pulmonary failure complicating therapy with high-dose Ara-C in acute leukemia.
    Andersson BS; Cogan BM; Keating MJ; Estey EH; McCredie KB; Freireich EJ
    Cancer; 1985 Nov; 56(9):2181-4. PubMed ID: 4052964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bases for intravenous administration of cytosine arabinoside in the treatment of adult acute myeloid leukemia].
    Thomas X; Archimbaud E
    Bull Cancer; 1995 Nov; 82(11):911-22. PubMed ID: 8535017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebellar toxicity following high-dose cytosine arabinoside.
    Dworkin LA; Goldman RD; Zivin LS; Fuchs PC
    J Clin Oncol; 1985 May; 3(5):613-6. PubMed ID: 3998779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology of low-dose cytosine arabinoside.
    Spriggs D; Griffin J; Wisch J; Kufe D
    Blood; 1985 May; 65(5):1087-9. PubMed ID: 3995167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.